In 23 patients (14 diagnosed HCC, 7 with pancreatic carcinomas, and 2 with colorectal carcinomas), CD133‐targeting CAR‐T‐cells were administered which later on illustrated the elimination of CD133+ cells, alongside managed toxicity and effective disease stability. This evidence concerns the gene PROM1 and exocrine pancreatic carcinoma.